Background
Methods
Study design
Subjects
Clinical follow-up
Diagnostics
Statistics
Results
Study population
Patient characteristics
Respiratory Symptoms (n = 382) | |||
---|---|---|---|
Pneumonia (n = 112) | No Pneumonia (n = 270) | P-value | |
Gender (male/female) | 64/48 (57%/43%) | 114/156 (42%/58%) |
0.008
|
Age | 83 (7) | 83 (7) | 0.8 |
Weight | 65 (15) | 69 (17) |
0.05
|
Respiratory diseases | 41/109 (38%) | 90/262 (34%) | 0.5 |
- Asthma/COPD | 32/109 (30%) | 76/262 (29%) | 0.9 |
- Other lung disease | 11/109 (10%) | 29/262 (11%) | 0.9 |
Cardiovascular diseases | 80/109 (73%) | 202/262 (77%) | 0.4 |
- Stroke/TIA | 10/109 (9.2%) | 42/262 (16%) | 0.08 |
- Heart dysrythmia | 23/109 (21%) | 84/262 (32%) |
0.03
|
- Myocardial infarction | 18/109 (17%) | 38/262 (15%) | 0.6 |
- Heart failure | 24/109 (22%) | 69/262 (26%) | 0.4 |
- Hypertension | 52/109 (48%) | 120/262 (46%) | 0.7 |
- MCC | 34/108 (31%) | 87/261 (33%) | 0.7 |
Other diseases | 65/105 (62%) | 183/256 (71%) | 0.07 |
- Dementia | 22/105 (21%) | 55/256 (21%) | 0.9 |
- Depression | 5/105 (4.8%) | 20/256 (7.8%) | 0.3 |
- Rheumatic disease | 25/105 (24%) | 72/256 (28%) | 0.4 |
- Diapetes mellitus | 0.4 | ||
- Type 1 | 0/105 (0%) | 2/256 (0.8%) | |
- Type 2 | 19/105 (23%) | 58/256 (18%) | |
- Cancer status | 0.2 | ||
- Terminal | 2/105 (1.9%) | 9/256 (3.5%) | |
- Have been treated | 7/105 (6.7%) | 32/256 (13%) | |
- Under treatment | 6/105 (5.7%) | 20/256 (7.8%) | |
Smoking | 20/81 (25%) | 31/192 (16%) | 0.1 |
Virus detection
Respiratory symptoms (n = 382) | P-value | Pneumonia (n = 112) | P-value | |||
---|---|---|---|---|---|---|
Pneumonia (n = 112) | No pneumonia (n = 270) | Dyspnea (n = 57) | No dyspnea (n = 55) | |||
Rhinovirus | 12 (11%) | 23 (8.5%) | 0.5 | 8 (15%) | 4 (7.0%) | 0.2 |
Influenza virus | 7 (6.3%) | 28 (10.4%) | 0.2 | 2 (3.6%) | 5 (8.8%) | 0.4 |
Parainfluenza virus | 5 (4.5%) | 23 (8.5%) | 0.2 | 2 (3.6%) | 3 (5.3%) | 1.0 |
Coronavirus | 7 (6.3%) | 17 (6.3%) | 1.0 | 4 (7.3%) | 3 (5.3%) | 0.7 |
Respiratory syncytial virus | 3 (2.7%) | 19 (7.0%) | 0.1 | 3 (5.5%) | 0 (0%) | 0.1 |
Human metapneumovirus | 3 (2.7%) | 5 (1.9%) | 0.7 | 2 (3.6%) | 1 (1.8%) | 0.6 |
Adenovirus | 1 (0.89%) | 1 (0.37%) | 0.5 | 1 (1.8%) | 0 (0%) | 0.5 |
Bocavirus | 1 (0.89%) | 0 (0%) |
Na
| 1 (1.8%) | 0 (0%) | 0.5 |
1 or more viruses | 34 (30%) | 107 (40%) | 0.09 | 18 (33%) | 16 (28%) | 0.6 |
2 or more viruses | 7 (6.3%) | 13 (4.8%) | 0.6 | 4 (7.3%) | 3 (5.3%) | 0.7 |
White blood cell count and CRP-reactive protein level
Respiratorys symptoms (382) | P-value | Pneumonia (112) | P-value | |||
---|---|---|---|---|---|---|
Pneumonia (112) | No pneumonia (270) | Dyspnea (57) | No dyspnea (55) | |||
WBC | 13.8 (sd 14) | 11.1 (sd 9.3) | 0.07 | 12.4 (sd 5.7) | 15.1 (sd 19) | 0.3 |
WBC over 10 | 57 (51%) | 111 (42%) | 0.08 | 27 (47%) | 30 (56%) | 0.4 |
WBC over 15 |
29 (26%)
|
38 (14%)
|
0.006
| 14 (26%) | 15 (26%) | 1.0 |
CRP |
146 (sd 92)
|
105 (sd 79)
|
< 0.0001
| 158 (sd 95) | 134 (sd 88) | 0.2 |
CRP over 80 |
81 (72%)
|
151 (56%)
|
0.003
| 43 (78%) | 38 (67%) | 0.2 |
CRP over 100 |
71 (63%)
|
120 (44%)
|
0.0007
| 38 (69%) | 33 (58%) | 0.2 |
Pneumonia+/virus+ (1) | Pneumonia+/virus- (2) | Pneumonia−/virus+ (3) | Pneumonia−/virus- (4) | P (1vs2) | P (1vs3) | P (3vs4) | P (1vs4) | |
---|---|---|---|---|---|---|---|---|
WBC over 15 | 7 (21%) | 22 (29%) | 8 (7.5%) | 30 (19%) | 0.4 |
0.03
|
0.01
| 0.8 |
CRP over 100 | 24 (71%) | 47 (60%) | 40 (37%) | 80 (49%) | 0.3 |
0.001
| 0.06 |
0.02
|
Had a revisit | 11 (32%) | 26 (33%) | 32 (30%) | 67 (41%) | 0.9 | 0.8 | 0.06 | 0.3 |
Over 13 nights at ward | 11 (32%) | 23 (29%) | 28 (26%) | 59 (36%) | 0.8 | 0.5 | 0.08 | 0.7 |
Death at ward | 1 (2.9%) | 10 (13%) | 7 (6.5%) | 11 (6.8%) | 0.1 | 0.4 | 0.9 | 0.4 |
Clinical outcomes
Case number | Age range | Gender | Pneumonia | Dyspnea | Respiratory disease | Cardiovascular disease | Other disease | A respiratory virus | Over 13 nights at ward | WBC over 15 | CRP over 100 | Human metapneumovirus | Adenovirus | Rhinovirus | Influenza virus | Respiratory syncytial virus | Parainfluenza virus | Coronavirus |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 70–80 | M | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
2 | 90–100 | M | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
3 | 80–90 | F | 0 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
4 | 90–100 | F | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
5 | 90–100 | F | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
6 | 90–100 | F | 1 | 0 | 0 | 1 |
Na
| 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
7 | 90–100 | M | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
8 | 80–90 | M | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
9 | 80–90 | F | 1 | 0 | 0 | 0 |
Na
| 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
10 | 70–80 | M | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
11 | 70–80 | M | 0 | 1 | 0 | 1 |
Na
| 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
12 | 80–90 | M | 0 | 0 |
Na
|
Na
|
Na
| 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
13 | 80–90 | F | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
14 | 80–90 | M | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
15 | 90–100 | F | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
16 | 70–80 | M | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
17 | 90–100 | M | 1 | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
18 | 80–90 | F | 0 | 0 |
Na
|
Na
|
Na
| 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
19 | 70–80 | M | 0 | 1 | 1 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
20 | 80–90 | F | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
21 | 80–90 | F | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
22 | 70–80 | M | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
23 | 70–80 | M | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
24 | 80–90 | M | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
25 | 80–90 | M | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
26 | 80–90 | M | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
27 | 80–90 | F | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
28 | 80–90 | F | 1 | 1 |
Na
|
Na
|
Na
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
29 | 90–100 | M | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Σ | 11 | 9 | 17 | 17 | 8 | 19 | 9 | 21 | 1 | 0 | 2 | 0 | 0 | 4 | 1 | |||
% | 42 | 35 | 65 | 74 | 31 | 73 | 31 | 81 | 4 | 0 | 8 | 0 | 0 | 15 | 4 |
Variable | Over 13 nights at ward | Had a revisit | Exitus at ward | ||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95% limits | OR | 95% limits | OR | 95% limits | ||||
Pneumonia | 0.767 | 0.449 | 1.309 | 0.818 | 0.491 | 1.360 | 0.886 | 0.336 | 2.337 |
Leuk >15 | 1.303 | 0.690 | 2.460 | 1.336 | 0.726 | 2.461 | 1.158 | 0.376 | 3.565 |
CRP > 100 | 1.279 | 0.785 | 2.084 | 1.104 | 0.691 | 1.764 |
2.845
|
1.021
|
7.933
|
Virus | 0.736 | 0.450 | 1.203 |
0.620
|
0.385
|
0.998
| 0.836 | 0.318 | 2.199 |
Influenza virus | 0.480 | 0.188 | 1.221 | 0.441 | 0.181 | 1.071 | – | – | – |
Rhinovirus | 1.508 | 0.685 | 3.320 | 1.153 | 0.525 | 2.530 | 0.421 | 0.052 | 3.378 |
Coronavirus | 0.744 | 0.278 | 1.988 | 0.785 | 0.309 | 1.995 | 0.981 | 0.118 | 8.146 |